Examining FDA’s New Alternative Tools for Drug Pre-Approval and Pre-License Inspections
In late March 2025, The U.S. Department of Health and Human Services (“HHS”) announced that it would cut 3,500 full-time Food and Drug Administration (“FDA”) positions. HHS claimed that those cuts would be focused on “streamlining operations and centralizing administrative functions” and “not affect drug… reviewers, nor… impact inspectors.” The positions that FDA […]
Examining FDA’s New Alternative Tools for Drug Pre-Approval and Pre-License Inspections Read More »